




CARBOHYDRATE CHEMISTRY, BIOLOGY AND MEDICAL APPLICATIONS



EDITED BY

Hari G. Garg • Mary K. Cowman
Charles A. Hales

CARBOHYDRATE CHEMISTRY, BIOLOGY
AND MEDICAL APPLICATIONS

This page intentionally left blank

CARBOHYDRATE CHEMISTRY, BIOLOGY AND MEDICAL APPLICATIONS

Edited by

Hari G. Garg

*Harvard Medical School, Pulmonary and Critical Care Unit
Massachusetts General Hospital, Boston, MA, USA*

Mary K. Cowman

*Department of Chemical and Biological Sciences,
Polytechnic University, Brooklyn, NY, USA*

and

Charles A. Hales

*Harvard Medical School, Pulmonary and Critical Care Unit
Massachusetts General Hospital, Boston, MA, USA*



ELSEVIER

Amsterdam – Boston – Heidelberg – London – New York – Oxford
Paris – San Diego – San Francisco – Singapore – Sydney – Tokyo

Elsevier
Linacre House, Jordan Hill, Oxford OX2 8DP, UK
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands

First edition 2008

Copyright © 2008 Elsevier Ltd. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-08-054816-6

For information on all Elsevier publications
visit our website at books.elsevier.com

Printed and bound in China

08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

Dedication

To my wife, Mithlesh, and our children, Ashima and Arvin, for their loyal support and generous love.

Hari G. Garg

To my husband, Gene, and our son Rudd, for their loyal support and generous love.

Mary K. Cowman

To my wife, Mary Ann, and our sons, Sam, Chris, and John, for their loyal support and generous love.

Charles A. Hales

This page intentionally left blank

Contents

Preface	xi
Contributors	xiii
1. The Development of Carbohydrate Chemistry and Biology	1
<i>Derek Horton</i>	
I. Early History	1
II. The Contribution of Emil Fischer	2
III. Cyclic Forms	5
IV. Nomenclature of Carbohydrates	8
V. General Elucidation of Carbohydrate Structure	9
VI. Monosaccharide Structure	10
VII. Oligosaccharide Structure	11
VIII. Polysaccharide Structure	12
IX. Carbohydrate Antibiotics	14
X. Structural Methodology	15
XI. Carbohydrate Biochemistry	18
XII. Carbohydrate Antigens and Vaccines	20
XIII. Conclusion	21
2. Carbohydrate Structure Determination by Mass Spectrometry	29
<i>Bo Xie and Catherine E. Costello</i>	
I. Glycoproteins and Other Glycoconjugates	29
II. Instrumentation for Mass Spectrometry Applied to Carbohydrate Structural Determinations	34
III. Glycan Structural Determination by Mass Spectrometry	44
IV. Summary	52
3. Chemical Synthesis of Complex Carbohydrates	59
<i>Zhongwu Guo</i>	
I. Introduction	59
II. Glycosylation Methods in Carbohydrate Synthesis	60
III. Strategies for Oligosaccharide Assembly	65
IV. Chemical Synthesis of Glycosylphosphatidylinositols	70
V. Conclusion	75
4. Enzymatic Synthesis of Oligosaccharides and Conversion to Glycolipids	85
<i>Doris M. Su, Hironobu Eguchi, Chengfeng Xia, Jing Song, Wen Yi, Robert L. Woodward, and Peng G. Wang</i>	
I. Introduction	85
II. Oligosaccharide Biosynthesis-Associated Enzymes	86
III. Sugar Nucleotide Regeneration Systems	88

IV. Enzymatic Oligosaccharide Synthesis Processes	94
V. Conversion of Oligosaccharides to Glycolipids.	99
VI. Conclusion	102
5. Proteoglycans in the Lung.	113
<i>Mara S. Ludwig</i>	
I. Introduction.	113
II. Proteoglycans and Normal Lung Structure.	113
III. Contribution to Basic Lung Biology.	115
IV. Contribution of Proteoglycans to Normal Lung Mechanics.	115
V. Proteoglycans and Mechanical Strain	116
VI. Proteoglycans and the Developing Lung	118
VII. Role of Proteoglycans in Lung Disease	119
VIII. Conclusion.	125
6. Proteoglycans of the Intervertebral Disk	133
<i>Peter J. Roughley</i>	
I. Introduction.	133
II. Disk Proteoglycans	134
III. Aggrecan	134
IV. Versican	139
V. Link Protein	140
VI. Hyaluronan	141
VII. Small Leucine-Rich Repeat Proteoglycans	142
VIII. Perlecan	145
IX. Conclusion.	146
7. Small Leucine-Rich Repeat Proteoglycans of Skin.	155
<i>Paul G. Scott</i>	
I. Introduction.	155
II. Glycosaminoglycans and Proteoglycans of Skin	155
III. Small Leucine-Rich Repeat Proteins/Proteoglycans	156
IV. Decorin: The Major Small Leucine-Rich Repeat Proteoglycan of Skin	157
V. Biglycan	160
VI. Lumican and Fibromodulin	161
VII. Functions of Skin Leucine-Rich Repeat Proteoglycans.	162
VIII. Involvement of Skin Leucine-Rich Repeat Proteoglycans in Skin Pathology.	167
IX. Summary and Conclusions.	170
8. Functional Glycosaminoglycans in the Eye	181
<i>Masahiro Zako and Masahiko Yoneda</i>	
I. Introduction	181
II. Glycosaminoglycans in Eye Diseases	181
III. Glycosaminoglycans as Clinical Applications	194
IV. Conclusion	199
9. Biological Function of Glycosaminoglycans.	209
<i>Michael Roth, Eleni Papakonstantinou and George Karakiulakis</i>	
I. Introduction.	209
II. Biological Function of Glycosaminoglycans	210
III. Concluding Remarks	217

10. Physiological, Pathophysiological and Therapeutic Roles of Heparin/Heparan sulfate	227
<i>Jin Xie, Saravanababu Murugesan and Robert J. Linhardt</i>	
I. Introduction	227
II. Structure of Heparin and Heparan Sulfate	228
III. Blood Coagulation Processes	229
IV. Cell Growth and Differentiation	231
V. Inflammation	234
VI. Host Defense and Viral Infection Mechanisms	236
VII. Cell–Cell and Cell–Matrix Interactions	238
VIII. Lipid Transport and Clearance Metabolism	240
IX. Potential Therapeutic Roles of Heparin and Heparan Sulfate	242
11. Carbohydrates and Cutaneous Wound Healing	253
<i>Andrew Burd and Lin Huang</i>	
I. Introduction	253
II. Carbohydrate Polymers as Wound Dressings	254
III. Carbohydrate in Wound Healing Modulation	259
IV. Carbohydrate in Skin Tissue Engineering	264
V. Conclusions	269
12. Carbohydrates in Human Milk and Infant Formulas	275
<i>Günther Boehm, Bernd Stahl, Jan Knol and Johann Garssen</i>	
I. Introduction	275
II. Prebiotic Factors in Human Milk	276
III. Oligosaccharides of Nonhuman Milk Origin	277
IV. Prebiotic Effect of Nonmilk Oligosaccharides	279
V. Effect of Intestinal Microbiota on the Immune System: Preclinical Studies	283
VI. Effect of Intestinal Microbiota on the Immune System: Clinical Trials	284
VII. Conclusion	286
13. Role of Cell Surface Carbohydrates in Development and Disease	293
<i>Michiko N. Fukuda, Tomoya O. Akama and Kazuhiro Sugihara</i>	
I. Introduction	293
II. The Role of Cell Surface Carbohydrates in Reproduction and Development	293
III. The Role of Cell Surface Carbohydrates in Cancer	300
IV. Perspective	302
14. Therapeutic Use of Hyaluronan-Based Products	311
<i>Endre A. Balazs and Philip A. Band</i>	
I. Introduction	311
II. Ophthalmic Viscosurgery	311
III. Intra-Articular Hyaluronan: Viscosupplementation	314
IV. Tissue Augmentation	318
V. Hyaluronan for Antiadhesion, Wound Healing, and Matrix Engineering	322

15. Drug Delivery and Medical Applications of Chemically Modified Hyaluronan . . .	333
<i>Luis Z. Avila, Diego A. Gianolio, Paul A. Konowicz, Michael Philbrook, Michael R. Santos and Robert J. Miller</i>	
I. Introduction	333
II. Conjugation of Active Agents to Hyaluronan	334
III. Conjugation of Peptides and Proteins to Hyaluronan	340
IV. Drug Formulations Using Hyaluronan	342
V. Conclusion/Summary	347
16. Carbohydrate Microarrays as Essential Tools of Postgenomic Medicine.	359
<i>Xichun Zhou, Gregory T. Carroll, Craig Turchi and Denong Wang</i>	
I. Introduction	359
II. Carbohydrate Microarrays as Essential Tools in the Postgenomics Era	360
III. Progress in Developing Complementary Platforms of Carbohydrate Microarrays	365
IV. Conclusion Remarks.	380
17. Carbohydrate Arrays for Basic Science and as Diagnostic Tools	387
<i>Tim Horlacher, Jose L. de Paz and Peter H. Seeberger</i>	
I. Introduction	387
II. Carbohydrate Microarrays	388
III. Microarrays of Glycosaminoglycan Oligosaccharides for High-Throughput Screening Glycosaminoglycan-Protein Interactions	389
IV. Carbohydrate Microarrays to Detect Pathogens and Viruses.	396
V. Conclusions	399
Index	405

Preface

Carbohydrates are one of four major classes of biologically important molecules, the others being nucleic acids, proteins, and lipids. Historically, carbohydrate studies have dealt mainly with the structure and role of monosaccharides and small oligosaccharides (such as glucose, fructose, sucrose, and lactose) in cellular metabolism and fermentation processes, and the roles of polysaccharides such as cellulose in cell wall organization, and starch and glycogen as storage forms of glucose. The last fifty years have seen an explosion of knowledge about complex carbohydrate structures and their biological functions. First came structural studies that elucidated the role of cellulose in plant cell walls and chitin in invertebrates, as fibrillar assemblies providing mechanical strength. The glycosaminoglycans, their proteoglycans, and other network-forming polysaccharides such as alginates were found to give support to the polysaccharide or protein fibrillar components of the extracellular matrices of both plant and animal tissues. Thus mechanical and physical properties (tensile strength, viscoelasticity, osmotic pressure) were understood to depend on polysaccharides. More recently, other important roles have been elucidated for oligosaccharides, polysaccharides, glycoproteins, glycolipids and other complex glycoconjugates. These roles depend on specific receptor-ligand interactions, and control not only the organization of the pericellular and extracellular matrices, but also a myriad of cellular activities such as changes in gene expression through signaling pathways. Pathogen-host interactions, response to growth factors, inflammation, wound healing, a number of genetically linked disorders, and many other physiological processes depend on specific carbohydrate structures and interactions. This book is intended to assist physicians, glycobiologists, pharmaceutical scientists, and graduate students to gain an understanding the complex nature and functions of carbohydrates. The 17 chapters in this volume, written by renowned scientists and physicians working in the carbohydrate field, provide a broad overview of the chemistry, biology, and medical applications of carbohydrates.

The first four chapters deal with different aspects of carbohydrate chemistry. In Chapter 1, Derek Horton discusses the development of carbohydrate chemistry and biology from antiquity to the present and beyond and summarizes the structures and methods for structural analysis of complex carbohydrates. In Chapter 2, Bo Xie and Catherine Costello review the state-of-art application of mass spectrometry to the structural analysis of complex carbohydrates. In Chapter 3, Zhongwu Guo briefly summarizes the types of glycosylation methods and synthetic strategies that are commonly used in the chemical synthesis of glycoconjugates. Enzymes have simplified the synthesis of some oligosaccharides, and in Chapter 4,

Doris Su *et al.* review the enzymatic synthesis of oligosaccharides and their conversion to glycolipids.

Chapters 5–10 focus on the GAGs and heavily glycosylated proteins, that is, PGs. Malfunction either in the synthesis or in the breakdown of these macromolecules is associated with numerous human diseases. In Chapter 5, Mara Ludwig describes the contribution of different PGs to lung biology. Chapter 6, which includes the PGs of intervertebral disk, is by Peter Roughley. In Chapter 7, Paul Scott focuses on skin and its small leucine-rich repeat PGs. In Chapter 8, Masahiro Zako and Masahiko Yoneda discuss the role of GAGs in ocular pathogenic conditions. In Chapter 9, Michael Roth *et al.* summarize the biological functions of GAGs. In Chapter 10, Jin Xie *et al.* describe the physiological, pathophysiological, and therapeutic roles of heparin and heparan sulfate.

Carbohydrates are critical for biological activity. Chapters 11–17 address the therapeutic and diagnostic medical applications of carbohydrates. In Chapter 11, Andrew Burd and Lin Huang describe the use of carbohydrate polymers in wound dressings. In Chapter 12, Günther Boehm *et al.* review oligosaccharides in human milk and infant formulas. In Chapter 13, Michiko Fukuda *et al.* describe the role of cell surface carbohydrates in development and disease. In Chapters 14 and 15, Endre Balazs and Philip Band, and Luis Avila *et al.*, respectively, detail the medical use of hyaluronan-based therapeutic products and drug delivery and medical applications of chemically modified hyaluronan. Chapters 16 and 17 by Xichun Zhou *et al.*, and Tim Horlacher *et al.*, respectively, describe carbohydrate microarrays, which are being used to address specific challenges in carbohydrate research to provide novel medical diagnostic approaches and to unravel the functions of carbohydrates in health and disease.

Hari G. Garg
Mary K. Cowman
Charles A. Hales

Contributors

Tomoya O. Akama, Glycobiology Program, Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA

Luis Z. Avila, Genzyme Corporation, Drug and Biomaterial R&D, Waltham, Massachusetts, USA

Endre A. Balazs, Matrix Biology Institute, Edgewater, New Jersey, USA

Philip A. Band, Departments of Pharmacology and Orthopedic Surgery, New York University School of Medicine, New York, USA

Günther Boehm, Numico Research, Friedrichsdorf, Germany, and Sophia Children's Hospital, Erasmus University, Rotterdam, The Netherlands

Andrew Burd, Division of Plastic and Reconstructive Surgery, Department of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR

Gregory T. Carroll, Department of Chemistry, Columbia University, New York, USA

Catherine E. Costello, Center for Biomedical Mass Spectrometry, and Departments of Biochemistry and Biophysics, Boston University School of Medicine, Boston, Massachusetts, USA

Hironobu Eguchi, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Michiko N. Fukuda, Glycobiology Program, Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA

Johann Garssen, Numico Research, Wageningen, and Utrecht Institute for Pharmacological Sciences, Utrecht University, The Netherlands

Diego A. Gianolio, Genzyme Corporation, Drug and Biomaterial R&D, Waltham, Massachusetts, USA

Zhongwu Guo, Department of Chemistry, Wayne State University, Detroit, Michigan, USA

Tim Horlacher, Laboratory for Organic Chemistry, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland

Derek Horton, Department of Chemistry, American University, Washington DC, USA

Lin Huang, Division of Plastic and Reconstructive Surgery, Department of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR

George Karakiulakis, Department of Pharmacology, School of Medicine, Aristotle University, Thessaloniki, Greece

Jan Knol, Numico Research, Wageningen, The Netherlands

Paul A. Konowicz, Genzyme Corporation, Drug and Biomaterial R&D, Waltham, Massachusetts, USA

Robert J. Linhardt, Departments of Chemistry and Chemical Biology, Chemical and Biological Engineering, and Biology, Rensselaer Polytechnic Institute, Troy, New York, USA

Mara S. Ludwig, Meakins-Christie Laboratories, McGill University, Montreal, Canada

Robert J. Miller, Genzyme Corporation, Drug and Biomaterial R&D, Waltham, Massachusetts, USA

Saravanababu Murugesan, Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA

Eleni Papakonstantinou, Department Pharmacology, School of Medicine, Aristotle University, Thessaloniki, Greece

Jose L. de Paz, Laboratory for Organic Chemistry, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland

Michael Philbrook, Genzyme Corporation, Drug and Biomaterial R&D, Framingham, Massachusetts, USA

Michael Roth, Department of Internal Medicine, Pulmonary Cell Research, University Hospital, Basel, Switzerland, and Woolcock Institute for Medical Research, Molecular Medicine, Camperdown, Australia

Peter J. Roughley, Genetics Unit, Shriners Hospital for Children and Department of Surgery, McGill University, Montreal, Canada

Michael R. Santos, Genzyme Corporation, Drug and Biomaterial R&D, Framingham, Massachusetts, USA

Paul G. Scott, Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada

Peter H. Seeberger, Laboratory for Organic Chemistry, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland

Jing Song, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Bernd Stahl, Numico Research, Friedrichsdorf, Germany

Doris M. Su, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Kazuhiro Sugihara, Department of Obstetrics and Gynecology, Hamamatsu University, School of Medicine, Himamatsu, Japan

Craig Turchi, ADA Technologies, Inc., Littleton, Colorado, USA

Denong Wang, Stanford Tumor Glycome Laboratory, Stanford University School of Medicine, Stanford, California, USA

Peng G. Wang, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Robert L. Woodward, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Chengfeng Xia, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Bo Xie, Center for Biomedical Mass Spectrometry, Boston University School of Medicine, and Department of Chemistry, Boston University, Boston, Massachusetts, USA

Jin Xie, Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, New York, USA

Wen Yi, Departments of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio, USA

Masahiko Yoneda, Biochemistry and Molecular Biology Laboratory, Aichi Prefectural College of Nursing and Health, Nagoya, Japan

Masahiro Zako, Department of Ophthalmology, Aichi Medical University, Aichi, Japan

Xichun Zhou, ADA Technologies, Inc., Littleton, Colorado, USA

This page intentionally left blank

Chapter 1

The Development of Carbohydrate Chemistry and Biology

DEREK HORTON

Department of Chemistry, American University, Washington, DC 20016, USA

I. Early History

A major proportion of the organic matter on Earth is plant tissue (“biomass”) and is composed of carbohydrates, principally cellulose. This is the structural support polymer of land plants and the material used since ancient times in the form of cotton and linen textiles, and later as paper. Chitin is a polymer related to cellulose that has skeletal function in arthropods and fungi. Other polymeric carbohydrates constitute the structural support framework for marine plants and the cell walls of microorganisms. The sweet carbohydrate of sugar cane, now termed sucrose, has been a dietary item for at least 10 millennia.

Ranking alongside cellulose in abundance is starch, a biopolymer that is the food-reserve carbohydrate of photosynthetic plants, and the closely related glycogen, the storage carbohydrate in the animal kingdom. Starch occurs as microscopic granules in plant storage tissue (cereal grains, tubers), and the process for its isolation was clearly described by Cato the Elder (1): steeping the grains in cold water to swell them, straining off the husks, and allowing the milky suspension to settle to afford, after drying, a white powder. This procedure is essentially the same as the modern corn wet-milling process, and the resultant starch powder is essentially pure carbohydrate whose molecular formula can be expressed as $C_6(H_2O)_5$, hence the term carbohydrate. It was used as early as 4000 BCE in Egypt as an adhesive with the cellulosic fiber of the papyrus plant to make writing material, and early in the first millennium CE for sizing paper and to stiffen cloth (2).

The photosynthetic apparatus in the green plant utilizes solar energy to effect the reduction of atmospheric carbon dioxide in a complex sequence of reactions (3,4) whose net result is the formation of glucose, a simple sugar (monosaccharide)

having the molecular formula $C_6H_{12}O_6$. Subsequent *in vivo* conversions afford carbohydrate polymers (polysaccharides), notably starch and cellulose, along with many related polymers formed from other monosaccharide sugars. In 1811, it was demonstrated (5) that acid hydrolysis of starch led to near-quantitative conversion into glucose, and later (6,7) it was shown that hydrolysis of cellulose likewise afforded glucose.

In the early nineteenth century, individual sugars were often named after their source, for example grape sugar (Traubenzucker) for glucose and cane sugar (Rohrzucker) for saccharose (the name sucrose was coined much later). The latter sugar was subsequently obtained from the juice of the sugar beet. During that century, a number of other simple sugars (monosaccharides) were isolated from acid hydrolyzates of other polysaccharide sources and were given names with the ending “-ose”; these include mannose, xylose, arabinose, and fucose. A nitrogen-containing sugar obtained by hydrolysis of chitin was termed glucosamine, and hydrolysis of milk sugar (lactose) led to galactose.

The name glucose was coined by Dumas in 1838 for the sugar obtained from honey, grapes, starch, and cellulose; 20 years later its molecular formula of $C_6H_{12}O_6$ was established, and subsequently it was shown to be a linear six-carbon aldehyde having hydroxyl groups on each of the chain carbon atoms. Polarimetric studies led Kekulé in 1866 to propose the name “dextrose” because glucose is dextrorotatory, and the levorotatory “fruit sugar” (Fruchtzucker, fructose) obtained by hydrolysis of cane sugar (sucrose) was for some time named “levulose.” The French word “cellule” for cell and the “-ose” suffix led to the term cellulose, long before its structure was known. The term “carbohydrate” (French “hydrate de carbone,” German “Kohlenhydrate”) was applied originally to monosaccharides in recognition of the fact that their empirical composition can be expressed as $C_n(H_2O)_m$. However, the term is now used generically in a wider sense.

II. The Contribution of Emil Fischer


During the last two decades of the nineteenth century, Emil Fischer (8) began his fundamental studies on carbohydrates, showing that phenylhydrazine reacts with glucose, mannose, and fructose to give the same crystalline phenylosazone, and he utilized the reaction introduced by Kiliani, the addition of hydrogen cyanide to a sugar, to give two isomeric acids. In his 1890 address to the German Chemical Society (9), he showed that “Traubenzucker” is a 2,3,4,5,6-pentahydroxyhexanal and that “Fruchtzucker” is a 1,3,4,5,6-pentahydroxy-2-hexanone.

The concept of stereochemistry, developed since 1874 by Van’t Hoff and Le Bel, had a great impact on carbohydrate chemistry because it could easily explain isomerism. From extensive chemical manipulations conducted with great skill, coupled with brilliant reasoning, Fischer correlated the families of sugars, and within 10 years, he was able to assign the relative configurations of most known sugars and to synthesize many additional examples (8). He introduced the “lock and key” hypothesis to interpret the action of an enzyme on a glycosidic substrate,

and his monumental achievements inspired a whole generation of researchers in the field of natural products (10).


To name the various compounds, Fischer and others laid the foundations of a terminology still in use, based on the terms triose, tetrose, pentose, and hexose. He endorsed Armstrong's proposal to classify sugars into aldoses and ketoses, and proposed the name fructose for levulose because he found that the sign of optical rotation was not a suitable criterion for grouping sugars into families.

The major transformations of the aldoses utilized by Fischer are illustrated in Scheme 1, wherein aldoses are converted by mild oxidation (bromine water) into aldonic acids, by reduction (originally sodium amalgam in ethanol, nowadays sodium borohydride) into alditols, by reaction with phenylhydrazine to form phenylosazones, and by vigorous oxidation (nitric acid) into aldaric acids. Reaction of an aldose with hydrogen cyanide creates a new asymmetric center and affords a pair of isomeric nitriles (termed epimers), convertible by a sequence of transformations (Fischer–Kiliani chain-ascent reaction) into a pair of higher aldoses. A reaction sequence (Ruff degradation) that essentially effects the reverse process converts an aldose into the corresponding lower aldose having one fewer carbon atom in the chain.




Scheme 1 Major transformations of aldoses.

Emil Fischer introduced the classical projection formulas for sugars, with a standard orientation (carbon chain vertical, carbonyl group at the top, Scheme 2); as he used models with flexible bonds between the atoms, he could easily “stretch” his sugar models into a position suitable for projection.




Scheme 2 The Fischer projection formula for a tetrahedrally substituted carbon atom.

He assigned to the dextrorotatory glucose (via the derived glucaric acid) the projection having the OH group at C-5 pointing to the right (Scheme 3), well knowing that there was a 50% chance that this was wrong. Much later, Bijvoet (11) proved Fischer's arbitrary assumption to be correct in the absolute sense, by using a special X-ray technique.



Scheme 3 D-Glucose, Fischer projection.


Rosanoff in 1906 (12) selected the enantiomeric glyceraldehydes as the point of reference; any sugar derivable by chain lengthening from what is now known as D-glyceraldehyde belongs to the D series, a convention still in use (Scheme 4).



Scheme 4 D-Glyceraldehyde.

For a sugar having n stereocenters, there are 2^n isomers, so that there are $2^4=16$ aldohexoses, 8 in the D series and 8 in the L series. The names of the D-aldoses and their stereochemical relationships are illustrated in Scheme 5. These names form the basis of the group-configurational designators: *allo*, *altro*, *gluco*,

manno, *gulo*, *ido*, *galacto*, and *talo* for four stereocenters; *ribo*, *arabino*, *xyl*, and *lyxo* for three stereocenters; and *erythro* and *threo* for two stereocenters.



Scheme 5 The D family of aldoses.

The Cahn–Ingold–Prelog *R,S* system of stereodesignators (13), introduced much later for naming other natural products, is not used for sugars as it would lead to unwieldy names.

III. Cyclic Forms

Toward the end of the nineteenth century, it was realized that the free sugars exist as cyclic hemiacetals or hemiketals. Individual sugars react with methanol under acid catalysis to give stable products termed methyl glycosides, which are mixed full acetals. These have a new asymmetric center at the original carbonyl atom and were thus isolated as pairs of isomers that were designated as the α and β forms, later termed anomers. In the D series, the α anomer was defined as the one having the more-positive specific rotation, and in the L series, the α anomer